GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CARsgen Therapeutics Holdings Ltd (HKSE:02171) » Definitions » Beneish M-Score

CARsgen Therapeutics Holdings (HKSE:02171) Beneish M-Score : 0.00 (As of Apr. 01, 2025)


View and export this data going back to 2021. Start your Free Trial

What is CARsgen Therapeutics Holdings Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for CARsgen Therapeutics Holdings's Beneish M-Score or its related term are showing as below:

During the past 6 years, the highest Beneish M-Score of CARsgen Therapeutics Holdings was 0.00. The lowest was 0.00. And the median was 0.00.


CARsgen Therapeutics Holdings Beneish M-Score Historical Data

The historical data trend for CARsgen Therapeutics Holdings's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CARsgen Therapeutics Holdings Beneish M-Score Chart

CARsgen Therapeutics Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Beneish M-Score
Get a 7-Day Free Trial - - - - -

CARsgen Therapeutics Holdings Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of CARsgen Therapeutics Holdings's Beneish M-Score

For the Biotechnology subindustry, CARsgen Therapeutics Holdings's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CARsgen Therapeutics Holdings's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CARsgen Therapeutics Holdings's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where CARsgen Therapeutics Holdings's Beneish M-Score falls into.


;
;

CARsgen Therapeutics Holdings Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of CARsgen Therapeutics Holdings for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * +0.528 * +0.404 * +0.892 * +0.115 *
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * +4.679 * -0.327 *
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec24) TTM:Last Year (Dec23) TTM:
Total Receivables was HK$30.01 Mil.
Revenue was HK$42.09 Mil.
Gross Profit was HK$15.75 Mil.
Total Current Assets was HK$1,633.83 Mil.
Total Assets was HK$1,786.25 Mil.
Property, Plant and Equipment(Net PPE) was HK$132.34 Mil.
Depreciation, Depletion and Amortization(DDA) was HK$35.97 Mil.
Selling, General, & Admin. Expense(SGA) was HK$55.55 Mil.
Total Current Liabilities was HK$271.20 Mil.
Long-Term Debt & Capital Lease Obligation was HK$141.67 Mil.
Net Income was HK$-852.14 Mil.
Gross Profit was HK$0.00 Mil.
Cash Flow from Operations was HK$-437.42 Mil.
Total Receivables was HK$10.71 Mil.
Revenue was HK$0.00 Mil.
Gross Profit was HK$0.00 Mil.
Total Current Assets was HK$2,048.74 Mil.
Total Assets was HK$2,468.89 Mil.
Property, Plant and Equipment(Net PPE) was HK$395.28 Mil.
Depreciation, Depletion and Amortization(DDA) was HK$95.59 Mil.
Selling, General, & Admin. Expense(SGA) was HK$46.83 Mil.
Total Current Liabilities was HK$214.62 Mil.
Long-Term Debt & Capital Lease Obligation was HK$77.08 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(30.014 / 42.093) / (10.71 / 0)
=0.71304 /
=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0 / 0) / (15.745 / 42.093)
= / 0.374053
=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1633.832 + 132.337) / 1786.252) / (1 - (2048.744 + 395.281) / 2468.893)
=0.011243 / 0.010073
=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=42.093 / 0
=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(95.591 / (95.591 + 395.281)) / (35.974 / (35.974 + 132.337))
=0.194737 / 0.213735
=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(55.545 / 42.093) / (46.832 / 0)
=1.319578 /
=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((141.674 + 271.196) / 1786.252) / ((77.076 + 214.618) / 2468.893)
=0.231138 / 0.118148
=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-852.143 - 0 - -437.415) / 1786.252
=-0.232178

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.


CARsgen Therapeutics Holdings Beneish M-Score Related Terms

Thank you for viewing the detailed overview of CARsgen Therapeutics Holdings's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


CARsgen Therapeutics Holdings Business Description

Traded in Other Exchanges
N/A
Address
No. 466 Yindu Road, Building 2, 1st Floor, Xuhui District, Shanghai, CHN
CARsgen Therapeutics Holdings Ltd is a clinical-stage biopharmaceutical company discovering, researching, and developing cell therapies in the People's Republic of China and the United States of America.
Executives
Bei Jing Shen Nong Tou Zi Guan Li Gu Fen You Xian Gong Si 2102 Investment manager
Candock Holdings Limited 2501 Other
Yi Jie Sheng Wu Ji Shu Kong Gu You Xian Gong Si 2501 Other
Yi De Kong Gu You Xian Gong Si 2501 Other
Quan Zhou Shi Ding Wo Chuang Feng Tou Zi Zhong Xin You Xian He Huo 2501 Other
Yang Xuehong 2501 Other
Wang Huamao 2401 A concert party to an agreement to buy shares
Li Zonghai 2401 A concert party to an agreement to buy shares
Guo Bingsen 2401 A concert party to an agreement to buy shares
Accure Biotech Limited 2501 Other
Cart Biotech Limited 2501 Other
Chen Haiou 2501 Other
Guo Xiaojing 2501 Other
He Xi Holdings Limited 2501 Other
Redelle Holding Limited 2501 Other

CARsgen Therapeutics Holdings Headlines

No Headlines